NewsWatcher

PBR Nachrichten

PBR (Pharmaceutical Business Review) ist ein Onlineportal mit News zur Pharma- und Biotechnologiebranche. Die Redaktion berichtet über neue Medikamente und deren Zulassungsverfahren, sowie über geschäftliche Entwicklungen von Pharmaunternehmen.
 
30.03.17 - 11:37
Warp Drive Bio forms technology alliance with GSK (PBR)
 
Warp Drive Bio has partnered with GSK to discover potential therapeutics in oncology and other diseases....
30.03.17 - 11:37
Ritter reports topline Ph2b/3 results for lactose intolerance treatment RP-G28 (PBR)
 
Ritter Pharmaceuticals' lactose intolerance treatment, RP-G28, demonstrated efficacy and clinically meaningful benefit in phase 2b/3 clinical trial....
30.03.17 - 10:01
FDA approves Roche′s Ocrevus for relapsing and primary progressive MS (PBR)
 
Roche has secured approval from the US Food and Drug Administration (FDA) for its Ocrevus (ocrelizumab) to treat patients with relapsing and primary progressive forms of multiple sclerosis (MS)....
29.03.17 - 03:37
FDA grants priority review for Lynparza for maintenance setting in ovarian cancer patients (PBR)
 
The US Food and Drug Administration (FDA) has accepted AstraZeneca's new drug application (NDA) for Lynparza (olaparib) tablets (300mg twice daily) for use in platinum-sensitive, relapsed ovarian cancer patients in the maintenance setting....
28.03.17 - 13:25
FDA approves Tesaro′s Zejula for recurrent ovarian cancer (PBR)
 
Tesaro has secured approval from the US Food and Drug Administration (FDA) for Zejula (niraparib) for women with recurrent ovarian cancer....
28.03.17 - 12:49
Summit to extend PhaseOut DMD trial for ezutromid (PBR)
 
Summit Therapeutics has announced that, subject to regulatory approval, it will go ahead with the planned extension phase of PhaseOut DMD, a Phase 2 clinical trial studying the utrophin modulator ezutromid....
28.03.17 - 12:49
University of Dundee secures grant to discover new antibacterial drugs (PBR)
 
University of Dundee in the UK has been awarded almost £1m to boost efforts to identify new new antibiotics to tackle bacterial infections....
28.03.17 - 09:54
Allergan, Paratek′s acne drug succeeds in two phase 3 trials (PBR)
 
Allergan and Paratek Pharmaceuticals' acne drug sarecycline has met its primary efficacy endpoints in two phase 3 trials....
27.03.17 - 12:25
Xenon′s acne drug XEN801 fails in phase 2 trial (PBR)
 
A phase 2 trial of Xenon Pharmaceuticals' acne drug XEN801 has failed to meet its efficacy endpoints in patients having moderate to severe acne....
27.03.17 - 12:25
Ignyta to explore strategic options for cancer candidate taladegib (PBR)
 
Ignyta is exploring strategic options for taladegib and has entered into an amended and restated license, development and commercialization agreement with Eli Lilly and Company for the taladegib oncology program....
27.03.17 - 12:25
PureTech signs licensing and equity deal with Novartis to advance clinical stage mTORC1 programs (PBR)
 
PureTech Health has signed a licensing and equity agreement with Novartis to advance two clinical-stage programs targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway....
27.03.17 - 09:25
Genentech′s Rituxan gets FDA breakthrough therapy status to treat pemphigus vulgaris (PBR)
 
Roche's subsidiary Genentech has secured breakthrough therapy status from the US Food and Drug Administration (FDA) for its Rituxan (rituximab) to treat pemphigus vulgaris....
24.03.17 - 11:25
Amgen′s Amgevita secures approval in Europe for certain inflammatory diseases (PBR)
 
Amgen's Amgevita (biosimilar adalimumab) has been granted the marketing authorization by the European Commission (EC) in all available indications....
24.03.17 - 11:25
Merck, Pfizer get FDA nod for Bavencio to treat metastatic Merkel cell carcinoma (PBR)
 
Merck's EMD Serono and Pfizer have secured approval from the US Food and Drug Administration (FDA) for Bavencio (avelumab) injection 20 mg/mL to treat metastatic Merkel cell carcinoma (mMCC)....
24.03.17 - 11:25
BioLineRx acquires UK cancer immunotherapeutics company Agalimmune (PBR)
 
Clinical-stage biopharmaceutical firm BioLineRx has purchased Agalimmune, a private UK-based company with an anti-cancer immunotherapy platform....
23.03.17 - 12:01
GSK, Regeneron to mine gene data from 500000 volunteer participants in UK (PBR)
 
Regeneron Pharmaceuticals announced a major research initiative among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate genetic sequence data from the 500,000 volunteer participants in the U.K. Biobank resource....
23.03.17 - 12:01
Akashi gets FDA nod to restart clinical development of DMD drug HT-100 (PBR)
 
Akashi Therapeutics has secured approval from the US Food and Drug Administration (FDA) to resume clinical development of HT-100 (delayed-release halofuginone) in patients with any of the genetic mutations that cause Duchenne muscular dystrophy (DMD)...
23.03.17 - 12:01
Biogen wins patent ruling in multiple sclerosis drug case (PBR)
 
Biogen has won an intellectual property rights ruling over its multiple sclerosis (MS) drug candidate, Tecfidera following a favorable decision from the US Patent and Trademark Office's Patent Trial and Appeal Board....
23.03.17 - 09:50
Novartis′ serelaxin fails to meet primary endpoint in heart failure study (PBR)
 
Novartis' RLX030 (serelaxin) has failed to meet its primary endpoint in a phase III acute heart failure (AHF) study....
22.03.17 - 12:13
X-Chem, Ono to collaborate on multi-target drug discovery (PBR)
 
X-Chem, a biotechnology firm focused on developing novel small molecule therapeutics by applying its innovative drug discovery platform, has entered into a partnership with Ono Pharmaceutical....
22.03.17 - 12:13
Pierre Fabre, H-Immune partner on immuno-oncology therapeutics (PBR)
 
French pharma Pierre Fabre has entered into a strategic research partnership with H-Immune to develop immuno-oncology therapeutics using the latter's technology platform to generate lead candidates of fully human antibodies....
22.03.17 - 09:38
Newron′s Xadago gets FDA nod to treat Parkinson′s disease (PBR)
 
Newron Pharmaceuticals, along with its partners Zambon and US WorldMeds, has secured approval from the US the Food and Drug Administration (FDA) for its Xadago (safinamide) to treat patients with Parkinson's disease (PD)....
21.03.17 - 11:49
Nektar′s NKTR-181 shown to reduce chronic pain in phase 3 trial (PBR)
 
Nektar Therapeutics' NKTR-181 has met primary and secondary endpoints in phase 3 SUMMIT-07 study in chronic pain....
21.03.17 - 11:49
SalvaRx to invest in Rift Biotherapeutics (PBR)
 
SalvaRx, a subsidiary of SalvaRx Group, has agreed to invest in Delaware-based biotechnology company Rift Biotherapeutics which focuses on the development of antibodies for use in oncology....
21.03.17 - 11:49
Lilly′s abemaciclib meets primary endpoint in phase 3 breast cancer trial (PBR)
 
A phase 3 study of Lilly's breast cancer drug, abemaciclib, in combination with fulvestrant, has met its primary endpoint of progression-free survival (PFS)....
21.03.17 - 08:13
Bristol-Myers Squibb, CytomX extend cancer collaboration (PBR)
 
Bristol-Myers Squibb (BMS) is paying CytomX Therapeutics $200m upfront to add up to eight new candidates to their existing Probody therapeutics collaboration....
20.03.17 - 12:13
Oxford BioDynamics participates in rheumatoid arthritis triggers study (PBR)
 
Oxford BioDynamics is participating in a collaboration to identify the biological factors that trigger disease relapses, known as flares, in Rheumatoid Arthritis (RA), entitled the BIO-FLARE study (Biological factors that limit sustained remission in...
20.03.17 - 11:25
Circassia signs deal for US rights to two AstraZeneca COPD drugs (PBR)
 
UK-based Circassia Pharmaceuticals has agreed to pay up to $230m for certain US commercial rights for Tudorza and Duaklir, two drugs developed by AstraZeneca to treat chronic obstructive pulmonary disease (COPD)....
20.03.17 - 11:25
Novartis′ heart failure drug Entresto improves glycemic control in Phase III study (PBR)
 
Novartis has unveiled results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes indicating that Entresto (sacubitril/valsartan) tablets enahanced glycemic control, as evaluated by h...
20.03.17 - 09:25
Amgen′s cholesterol drug shows positive effect in cardiovascular outcomes study (PBR)
 
Amgen's cholesterol drug Repatha (evolocumab) has showed positive effect in a 27,564-patient cardiovascular outcomes study....
17.03.17 - 10:13
Shire′s HAE drug Cinryze secures label extension in Europe (PBR)
 
Shire has secured label expansion approval from the European Commission for its hereditary angioedema therapy Cinryze....
17.03.17 - 08:49
Cell Medica raises £60m to advance multiple cancer programmes (PBR)
 
Cellular immunotherapy company, Cell Medica has secured £60m in a Series C financing round with participation from existing investors Touchstone Innovations, funds managed by Woodford Investment Management, and funds managed by Invesco Perpetual....
17.03.17 - 08:49
PTC Therapeutics agrees to buy Marathon′s DMD drug for $140m (PBR)
 
PTC Therapeutics has agreed to acquire all rights to Emflaza (deflazacort) from Marathon Pharmaceuticals....
16.03.17 - 13:01
Catalyst Pharmaceuticals′ neuromuscular drug succeeds in seven-patient trial (PBR)
 
Catalyst Pharmaceuticals said its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a debilitating neuromuscular disease, met the main goals of a study....
16.03.17 - 13:01
Scientists link noncoding genetic variants to neurodevelopmental disorders (PBR)
 
Scientists from the Max Planck Institute for Psycholinguistics and Radboud University in Nijmegen found that genetic variation in the non-coding DNA may lead to language impairments in children and other neurodevelopmental disorders such as schizophr...
16.03.17 - 13:01
UK′s MHRA grants early access to Sanofi′s dermatology treatment (PBR)
 
The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Sanofi's dupilumab, an investigational treatment for atopic dermatitis (AD), a positive scientific opinion through the Early Access to Medicines Scheme (EAMS)....
15.03.17 - 14:25
CRISPR Therapeutics licenses cell engineering platform from MaxCyte (PBR)
 
CRISPR Therapeutics and Casebia Therapeutics, its joint venture with Bayer, have signed a licensing agreement for a cell transfection platform from MaxCyte....
15.03.17 - 14:25
AstraZeneca′s Lynparza shows significant survival benefit in ovarian cancer study (PBR)
 
A phase 3 clinical trial evaluating AstraZeneca's PARP inhibitor Lynparza (olaparib) as maintenance therapy in ovarian cancer demonstrated a pronounced extension in survival compared to placebo....
15.03.17 - 12:13
Pfizer launches Zavicefta in UK and Germany (PBR)
 
Pfizer has launched Zavicefta (ceftazidime/avibactam), a combination antibiotic to treat Gram-negative bacterial infections requiring hospitalization, in the UK and Germany....
15.03.17 - 08:49
FDA approves Merck′s Keytruda for Hodgkin lymphoma (PBR)
 
Merck has secured another approval from from the US Food and Drug Administration (FDA) for Keytruda, this time for classical Hodgkin lymphoma....
14.03.17 - 11:49
Indivior plans to file NDA for schizophrenia drug in Q4 2017 (PBR)
 
Indivior has unveield positive top-line 12-Month phase 3 results confirming long-term safety profile of RBP-7000 in patients with schizophrenia....
14.03.17 - 11:49
Daiichi Sankyo enters into drug discovery and licensing deal with Heptares (PBR)
 
Daiichi Sankyo has signed an agreement with Heptares Therapeutics to discover and develop small-molecules for the treatment of pain....
14.03.17 - 11:49
Scientists use kiss of death to neutralize disease-causing proteins (PBR)
 
Scientists at the University of Dundee in Scotland have discovered how to destroy undruggable cancer proteins that lead to several strains of the disease....
14.03.17 - 09:13
FDA approves Novartis′ Kisqali to treat metastatic breast cancer (PBR)
 
Novartis has secured approval from the US Food and Drug Administration (FDA) for its Kisqali (ribociclib or LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy to treat metastatic breast cancer....
13.03.17 - 03:37
Synairgen eyes lung fibrosis trial after positive data from LOXL2 inhibitor program (PBR)
 
Synairgen is on track to begin the initial clinical trial of a new lung fibrosis treatment later this year after pre-clinical work showed more evidence of improved breathing....
10.03.17 - 12:25
Google′s venture arm leads $51.7m investment in Spero Therapeutics (PBR)
 
Spero Therapeutics, a biopharmaceutical firm engaged in the development of novel therapies to treat bacterial infections, has completed a $51.7m Series C preferred financing led by new investor GV (formerly Google Ventures)....
10.03.17 - 12:25
FDA grants orphan drug status to Boehringer′s BI 836858 to treat MDS (PBR)
 
Boehringer Ingelheim has secured orphan drug designation from the US Food and Drug Administration (FDA) for its anti-CD33 monoclonal antibody, BI 836858, to treat myelodysplastic syndromes (MDS)....
10.03.17 - 09:13
Pfizer, Servier get FDA nod to start US testing of UCART19 (PBR)
 
Servier and Pfizer have secured clearance from the US Food and Drug Administration (FDA) to go ahead with the clinical development of UCART19, an allogeneic, gene-edited cellular therapy candidate to treat relapsed/refractory acute lymphoblastic leuk...
09.03.17 - 11:49
BerGenBio signs deal with Merck to test lung and breast cancer combo (PBR)
 
BerGenBio has signed a collaborative agreement with Merck focused the clinical study of BGB324 with Keytruda (pembrolizumab) in patients with advanced non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC)....
09.03.17 - 11:49
Heat Biologics to acquire controlling stake in Pelican Therapeutics (PBR)
 
Heat Biologics has agreed to buy an 80% controlling stake in Pelican Therapeutics, a privately held immuno-oncology company engaged in the development of agonists to TNFRSF25, a differentiated T cell costimulatory receptor....





































 

>Aktiensuche

>Wertpapiersuche

>Finanznachrichten posten

Boersentreff Media:            >Impressum            >Über uns            >Werbung            >Newstechnologie

>Zitat des Tages: Das Ende der Vergötzung von Vernunft und Wissenschaft wäre der Anfang eines neuen Wissens: daß nur die Umkehr der Herzen und eine neue Verantwortung uns weiterhelfen können. - Franz Alt

Partner:    >Tradegate Börse | >DB Xmarkets | >TraderFox Handelssignale | >Heibel-Ticker Börsenbrief | >Finanzlinks

Börsentreff auf Facebook | Börsentreff auf Twitter

Copyright @ Boersentreff.de - Die Märkte im Blick!